Table 3. Meta-analysis of miR-196a2 rs11614913 polymorphism with cancer risk.

Variables	na	T vs. C				TT vs. CC				CT vs. CC				TT+CT vs. CC				TT vs. CT+CC
		OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2	OR(95% CI)	P	P-H	I2
Total	38	0.949(0.902–0.998)	0.044	<0.001	58.2	0.861(0.772–0.959)	0.007	<0.001	58.7	1.033(0.951–1.123)	0.441	<0.001	56.6	0.984(0.909–1.065)	0.685	<0.001	60.0	0.865(0.802–0.934)	<0.001	0.002	45.2
Cancer type
Bladder Cancer	2	1.032(0.906–1.174)	0.639	0.562	0.0	0.961(0.724–1.277)	0.786	0.224	32.4	1.192(0.837–1.696)	0.331	0.106	61.7	1.102(0.915–1.327)	0.307	0.171	46.5	0.738(0.320–1.701)	0.476	0.100	63.1
Breast Cancer	8	0.978(0.868–1.102)	0.716	0.002	68.3	0.903(0.699–1.167)	0.436	0.004	66.9	0.976(0.888–1.074)	0.623	0.12	38.9	0.989(0.841–1.164)	0.898	0.014	60.3	0.915(0.765–1.095)	0.334	0.031	54.5
Colorectal Cancer	6	0.910(0.794–1.043)	0.177	0.061	52.6	0.754(0.627–0.907)	0.003	0.108	44.6	0.878(0.755–1.021)	0.091	0.168	35.9	0.848(0.735–0.979)	0.025	0.082	48.9	0.838(0.721–0.974)	0.021	0.165	36.3
ESCC	2	0.863(0.551–1.351)	0.518	0.001	90.6	0.685(0.209–2.245)	0.532	<0.001	93.9	1.166(0.692–1.962)	0.564	0.030	78.7	1.020(0.537–1.935)	0.953	0.005	87.3	0.610(0.268–1.390)	0.240	0.001	91.4
Gastric Cancer	2	0.893(0.778–1.024)	0.104	0.230	30.5	0.803(0.608–1.062)	0.125	0.306	4.5	0.839(0.653–1.077)	0.167	0.163	48.5	0.819(0.647–1.037)	0.097	0.162	48.8	0.894(0.722–1.107)	0.305	0.698	0.0
Lung Cancer	4	0.893(0.821–0.971)	0.008	0.149	43.8	0.794(0.672–0.938)	0.007	0.259	25.5	0.991(0.771–1.274)	0.945	0.059	59.7	0.935(0.745–1.175)	0.565	0.075	56.6	0.842(0.737–0.962)	0.011	0.201	0.201
Primary Liver Cancer	5	0.890(0.767–1.032)	0.123	0.034	61.7	0.790(0.589–1.061)	0.117	0.041	59.8	0.873(0.754–1.010)	0.068	0.776	0.0	0.859(0.748–0.986)	0.030	0.334	12.5	0.871(0.690–1.100)	0.248	0.043	59.4
SCCHN	4	1.067(0.965–1.179)	0.205	0.442	0.0	1.241(0.841–1.831)	0.276	0.099	63.3	1.490(0.835–2.658)	0.177	0.006	86.7	1.123(0.851–1.481)	0.413	0.006	76.1	0.948(0.797–1.127)	0.544	0.683	0.0
other	5	1.026(0.928–1.135)	0.613	0.352	9.5	0.966(0.776–1.201)	0.754	0.491	0.0	1.306(1.106–1.542)	0.002	0.188	34.9	1.212(1.035–1.419)	0.017	0.159	39.3	0.853(0.716–1.017)	0.076	0.720	0.0
Ethnicity
Caucasian	14	0.981(0.894–1.076)	0.683	0.002	61.8	0.934(0.766–1.138)	0.496	0.003	61.7	1.023(0.946–1.108)	0.565	0.3	14.7	0.989(0.895–1.092)	0.825	0.048	42.3	0.918(0.788–1.070)	0.276	0.035	47.1
Asian	24	0.934(0.879–0.991)	0.025	0.001	55.0	0.827(0.727–0.940)	0.004	0.001	55.5	1.043(0.924–1.177)	0.500	<0.001	65.9	0.986(0.878–1.107)	0.808	<0.001	66.6	0.845(0.773–0.923)	<0.001	0.011	44.1
Design
HB	21	0.918(0.855–0.986)	0.019	<0.001	64.5	0.849(0.726–0.993)	0.040	<0.001	69.5	0.997(0.881–1.127)	0.956	<0.001	63.4	0.946(0.842–1.064)	0.355	<0.001	65.6	0.848(0.763–0.942)	0.002	0.001	56.4
PB	14	0.963(0.916–1.012)	0.132	0.152	29.2	0.869(0.783–0.966)	0.009	0.553	0.0	1.064(0.943–1.201)	0.314	0.024	48.9	1.011(0.907–1.127)	0.843	0.022	48.5	0.908(0.832–0.991)	0.031	0.525	0.0
Sample size
≥1000	11	0.941(0.904–0.979)	0.003	0.131	33.5	0.880(0.811–0.955)	0.002	0.143	32.0	0.964(0.902–1.031)	0.287	0.085	39.6	0.936(0.857–1.021)	0.137	0.048	45.8	0.904(0.845–0.966)	0.003	0.593	0.0
<1000	27	0.966(0.889–1.050)	0.416	<0.001	65.0	0.854(0.709–1.029)	0.098	<0.001	65.4	1.092(0.959–1.243)	0.183	<0.001	60.3	0.835(0.769–0.907)	<0.001	<0.001	64.4	0.833(0.729–0.952)	0.007	<0.001	55.3
HWE
Yes	32	0.929(0.884–0.977)	0.004	<0.001	55.1	0.851(0.763–0.948)	0.003	<0.001	58.7	0.990(0.914–1.073)	0.815	0.001	50.9	0.948(0.874–1.028)	0.196	<0.001	56.8	0.863(0.800–0.931)	<0.001	0.004	44.7

ESCC: esophageal squamous cell carcinoma; SCCHN: squamous cell carcinoma of the head and neck; HB: hospital based; PB: population based; HWE: Hardy-Weinberg equilibrium; OR: odds ratio; CI: confidence interval; P: p value; P-H: P value of Q for heterogeneity test; I²: 0–25%, no heterogeneity; 25–50%, modest heterogeneity; 50%, high heterogeneity;

^aNumber of studies involved.

Random effects model was used when P value of Q for heterogeneity test (P-H) <0.05 or I²>50%; otherwise, fixed effect model was used.